Why $ZYNE skyrocketed this week

NASDAQ:ZYNE   Zynerba Pharmaceuticals, Inc
Jazz Pharmaceuticals $JAZZ agreed to buy GW Pharmaceuticals $GWPH for $7.2 billion last wednesday sending shares of fellow epilepsy-focused biotech companies $ZYNE flying.

"The acquisition allows Jazz to become a significant epilepsy player by adding Epidiolex, which exited 2020 with sales annualizing at about $576 million despite a challenging Covid environment and ahead of significant growth driven by a tuberous sclerosis label expansion and broad European launch,"


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.